Obinutuzumab plus Lenalidomide (GALEN) for the treatment of relapse/refractory aggressive lymphoma: a phase II LYSA study

Roch Houot; Guillaume Cartron; Fontanet Bijou; Sophie de Guibert; Gilles A Salles; Christophe Fruchart; Krimo Bouabdallah; Marie Maerevoet; Pierre Feugier; Steven Le Gouill; Hervé Tilly; Rene-Olivier Casasnovas; Cécile Moluçon-Chabrot; Eric Van Den Neste; Pierre Zachee; Marc Andre; Christophe Bonnet; Corinne Haioun; Achiel Van Hoof; Koen Van Eygen; Lysiane Molina; Emmanuelle Nicolas-Virelizier; Philippe Ruminy; Franck Morschhauser

doi:10.1038/s41375-018-0282-y

Obinutuzumab plus Lenalidomide (GALEN) for the treatment of relapse/refractory aggressive lymphoma: a phase II LYSA study

Leukemia. 2019 Mar;33(3):776-780. doi: 10.1038/s41375-018-0282-y. Epub 2018 Oct 5.

Authors

Roch Houot¹, Guillaume Cartron², Fontanet Bijou³, Sophie de Guibert¹, Gilles A Salles⁴, Christophe Fruchart⁵, Krimo Bouabdallah⁶, Marie Maerevoet⁷, Pierre Feugier⁸, Steven Le Gouill⁹, Hervé Tilly¹⁰, Rene-Olivier Casasnovas¹¹, Cécile Moluçon-Chabrot¹², Eric Van Den Neste¹³, Pierre Zachee¹⁴, Marc Andre¹⁵, Christophe Bonnet¹⁶, Corinne Haioun¹⁷, Achiel Van Hoof¹⁸, Koen Van Eygen¹⁹, Lysiane Molina²⁰, Emmanuelle Nicolas-Virelizier²¹, Philippe Ruminy¹⁰, Franck Morschhauser²²

Affiliations

¹ Department of Clinical Hematology, University Hospital of Rennes, Inserm 0203, University of Rennes, Rennes, France.
² Department of Clinical Hematology, University Hospital of Montpellier, UMR CNRS 5235, University of Montpellier, Montpellier, France.
³ French Blood Institute, Bordeaux, France.
⁴ Department of Hematology, Centre Hospitalier Lyon-Sud, Pierre Benite, France.
⁵ Institut d'Hématologie de Basse Normandie (IHBN), CHU, Caen, France.
⁶ Haematology, CHU de Bordeaux, Bordeaux, France.
⁷ Hematology, Institut Jules Bordet, Bruxelles, Belgium.
⁸ CHU et INSERM 954, Nancy Université, Vandoeuvre Les Nancy, France.
⁹ Department of Hematology, Nantes University Hospital and UMR892 INSERM, Nantes, France.
¹⁰ Centre Henri Becquerel, Inserm U918, Université de Rouen, IRIB, Rouen, France.
¹¹ Hematology, University Hospital, Dijon, France.
¹² Hematology Department, CHU Clermont Ferrand, Clermont-Ferrand, France.
¹³ Department of Hematology, Cliniques Universitaires Saint-Luc, Brussels, Belgium.
¹⁴ AZ GROENINGE, Kortrijk, Belgium.
¹⁵ Hematology Department, CHU UCL NAMUR, Yvoir, Belgium.
¹⁶ Clinical Hematology, CHU University of Liège, Liège, Belgium.
¹⁷ Hôpital Henri Mondor, Unité Hémopathies Lymphoide, Créteil, France.
¹⁸ General Hospital St-Jan, Brugge, Belgium.
¹⁹ ZNA Stuivenberg, Antwerp, Belgium.
²⁰ Hematology, CHU de Grenoble, Grenoble, France.
²¹ Hematology Department, Centre Léon Bérard, Lyon, France.
²² Université de Lille/ hopital Claude Huriez, Lille, France. franck.morschhauser@chru-lille.fr.

PMID: 30291335
DOI: 10.1038/s41375-018-0282-y

No abstract available

Publication types

Clinical Trial, Phase II
Multicenter Study
Research Support, Non-U.S. Gov't

MeSH terms

Aged
Aged, 80 and over
Angiogenesis Inhibitors / administration & dosage
Animals
Antibodies, Monoclonal, Humanized / administration & dosage
Antineoplastic Agents, Immunological / administration & dosage
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Female
Humans
Lenalidomide / administration & dosage
Lymphoma / drug therapy*
Male
Middle Aged
Neoplasm Recurrence, Local / drug therapy*
Recurrence

Substances

Angiogenesis Inhibitors
Antibodies, Monoclonal, Humanized
Antineoplastic Agents, Immunological
Lenalidomide
obinutuzumab